Holen Sie sich die Stockscreener-App
66.49
4.69%
-3.27
Abivax Adr Aktie (ABVX) Neueste Nachrichten
Leerink Partnrs Brokers Reduce Earnings Estimates for Abivax - Defense World
Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $78.75 - Defense World
Abivax (NASDAQ:ABVX) Reaches New 52-Week High on Analyst Upgrade - Defense World
Abivax SA Stock Surges on Promising Drug Results - TipRanks
Abivax (NASDAQ:ABVX) Trading 577.5% Higher on Analyst Upgrade - Defense World
Abivax SA Announces $608.6 Million Public Offering of ADSs - TipRanks
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating - TipRanks
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail
Abivax ADR Shows Rising Price Performance With Jump To 99 RS Rating - inkl
Abivax (NASDAQ:ABVX) Hits New 52-Week High on Analyst Upgrade - Defense World
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris - GlobeNewswire Inc.
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results - Investor's Business Daily
10 Best First Jobs for Aspiring CEOs - inkl
Prologis Inc (PLD) Stock: Navigating Drops and Gains - investchronicle.com
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod - TipRanks
Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment - TipRanks
Grid Metals (CVE:GRDM) Shares Up 44.4% – Here’s What Happened - Defense World
The ICU Stock Puzzle: Unraveling SeaStar Medical Holding Corp’s Fluctuating Performance - investchronicle.com
Citizens JMP reiterates Market Outperform rating on Abivax stock - Investing.com India
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact - TipRanks
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analyst Coverage Updates - The Globe and Mail
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease - TipRanks
Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks
Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Galapagos (GLPG) and Tenet Healthcare (THC) - The Globe and Mail
European ADRs Edge Up As Wisekey And ASML Lead Gains - Finimize
Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks
Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks
Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks
Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks
Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks
Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks
Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister
Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq
Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance
Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily
Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily
Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater
Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):